Trial Profile

A Phase II Two Cohorts Prospective Study to Evaluate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Tislelizumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

02 Dec 2021 According to a BeiGene media release, results from the study will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2021.
19 Nov 2021 Number of treatment arms have been increased from 1 to 2 by the addition of Tislelizumab plus chemotherapy plus Bevacizumab arm. Study design has been changed from single group assignment to parallel.
19 Nov 2021 Planned number of patients changed from 66 to 120.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com